157255-72-6

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Methyl-4-iodo-1-tritylimidazole is used as a key building block for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be incorporated into the development of new and innovative products within the pharmaceutical industry, contributing to the creation of novel drugs and therapeutic agents.
Used in Organic Material Synthesis:
In the field of organic materials, 2-Methyl-4-iodo-1-tritylimidazole is utilized as a component in the synthesis of different organic materials. Its properties make it suitable for enhancing the characteristics of these materials, potentially leading to advancements in areas such as materials science and chemical engineering.
2-METHYL-4-IODO-1-TRITYLIMIDAZOLE can be produced through various synthetic methods, making it accessible for research and commercial applications. It is available for purchase from chemical suppliers, ensuring that it can be readily incorporated into ongoing and future projects within the industries that benefit from its unique properties.

InChI:InChI=1/C23H19IN2/c1-18-25-22(24)17-26(18)23(19-11-5-2-6-12-19,20-13-7-3-8-14-20)21-15-9-4-10-16-21/h2-17H,1H3

Upstream product

• 73746-45-9 4-iodo-2-methyl-1H-imidazole 
• 76-83-5 trityl chloride 
• 73746-45-9 4⁽⁵⁾-iodo-2-methyl-1H-imidazole 

Downstream Products

• 1022155-26-5 C₃₉H₃₂F₆N₄O 
• 1021736-30-0 2-methyl-4-{[1-(trifluoromethyl)cyclopropyl]methyl}-1-trityl-1H-imidazole 
• 1022154-58-0 (2-methyl-1-trityl-1H-imidazol-4-yl)-(1-trifluoromethyl-cyclopropyl)-methanone 

Relevant academic research and scientific papers

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1

Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy. A number of IDO1 inhibitors have been identified, but only limited structural biology studies of IDO1 inhibitors are available t

Synthesis of 4,4'-biimidazoles

The palladium(0) catalysed coupling reaction of 4-iodo-1-triphenylmethylimidazole (7) or its 2-methyl analogue 8 afforded the 4,4'-biimidazoles 9 and 10, respectively. Treatment of these compounds with 60% aqueous trifluoroacetic acid gave 4,4'-biimidazole and 2,2'-dimethyl-4,4'-biimidazole as their bistrifluoroacetate salts 11 and 12, respectively.

Direct synthesis of pyrroles via a silver-promoted three-component reaction involving unusual imidazole ring opening

A novel silver-promoted three-component reaction toward the synthesis of multifunctionalized pyrroles has been developed. This reaction involves an unusual imidazole ring decomposition, presumably via 1,5-isomerization and subsequent hydrolysis.

Discovery of MK-5046, a potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity

We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-

Substituted inmidazoles as bombesin receptor subtype-3 modulators

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.